Technical Analysis for ZFGN - Zafgen, Inc.

Grade Last Price % Change Price Change
grade F 4.74 -0.21% -0.01
ZFGN closed down 0.21 percent on Friday, January 18, 2019, on 1.26 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ZFGN trend table...

Date Alert Name Type % Chg
Jan 18 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Lower Bollinger Band Walk Weakness 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Lower Bollinger Band Touch Weakness 0.00%
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 1,2,3 Retracement Bearish Bearish Swing Setup -0.21%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.21%
Jan 17 Pocket Pivot Bullish Swing Setup -0.21%
Jan 17 New 52 Week Low Weakness -0.21%

Older signals for ZFGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity. Beloranib, the Company’s product candidate, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms, including hyperphagia and obesity. Craniopharyngioma is a rare form of benign brain tumor that occurs near the optic nerve, pituitary gland and hypothalamus. Approximately 30% to 50% of cases of craniopharyngioma are diagnosed in childhood and adolescence.
Is ZFGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.355
52 Week Low 4.51
Average Volume 382,267
200-Day Moving Average 8.2585
50-Day Moving Average 6.3704
20-Day Moving Average 4.9595
10-Day Moving Average 4.928
Average True Range 0.332
ADX 36.11
+DI 10.6597
-DI 26.0254
Chandelier Exit (Long, 3 ATRs ) 4.574
Chandelier Exit (Short, 3 ATRs ) 5.506
Upper Bollinger Band 5.3192
Lower Bollinger Band 4.5998
Percent B (%b) 0.19
BandWidth 14.505495
MACD Line -0.367
MACD Signal Line -0.4395
MACD Histogram 0.0725
Fundamentals Value
Market Cap 130.27 Million
Num Shares 27.5 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -2.52
Price-to-Sales 0.00
Price-to-Book 0.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.27
Resistance 3 (R3) 5.25 5.07 5.18
Resistance 2 (R2) 5.07 4.93 5.07 5.15
Resistance 1 (R1) 4.90 4.85 4.99 4.92 5.12
Pivot Point 4.72 4.72 4.76 4.72 4.72
Support 1 (S1) 4.55 4.58 4.64 4.57 4.36
Support 2 (S2) 4.37 4.50 4.37 4.33
Support 3 (S3) 4.20 4.37 4.30
Support 4 (S4) 4.22